ChinaBio Partnering Forum EBD GroupChinaBIO
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

ChinaBio® Partnering Forum 2015 Program Overview

The preliminary program for ChinaBio® Partnering Forum 2015 will be available soon.

ChinaBio® Partnering Forum 2014 program

www.ebdgroup.com/cbpf/program
Tuesday, May 6, 2014
13:30–17:20
K1
Partnering Bootcamp: How to partner with global pharma more ►
Sponsored by:
Cooley LLPCooley LLP
17:30–19:30
Hotel Garden
ChinaBio® Partnering Forum Welcome Reception

All ChinaBio® Partnering Forum attendees are cordially invited to join us for the Welcome Reception.

You will be able to pick up your name badge at the Welcome Reception.

Presented by:
BayHelixBayHelix
Wednesday, May 7, 2014
08:00
Hotel Lobby
Registration opens
08:00–09:00
Grand Ballroom
Continental Breakfast
09:00–09:30
Welcome Remarks

Wednesday, 09:00–09:30
State Ballroom

Speakers:
  • Anna Chrisman – Director, Conferences and Program, EBD Group
  • Greg B. Scott – President and Founder, ChinaBio® LLC
  • Yuwen Liu, MBA – Chairwoman and CEO, BioBay
  • Barry Yang – Chairman, Suzhou Industrial Park
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:30–10:30
Keynote Panel
Changing roles of Western pharma in China

Wednesday, 09:30–10:30
State Ballroom

Partnering activity is exploding in China, setting new records in the number of deals, as well as the total and average deal values, which both doubled in 2013. This dynamic environment is rapidly changing the role of Western pharma in China. Just a few years ago, most big pharma focused on China as a sales outlet for the same drugs they were marketing to the global market. Now, nearly all have established major R&D centers here, and most have added dedicated business development teams that are seeking collaboration partners and novel assets throughout China. On this keynote panel, senior executives from several global pharma will examine how the rapidly changing landscape in China is driving their companies to adapt new research and development models to address the local market needs as well as the need for novel NMEs globally.

Moderator:
Greg B. Scott – President and Founder, ChinaBio® LLC

Panelists:
  • Graham R. Brazier – VP, Business Development, Bristol-Myers Squibb
  • Darren Ji, MD, PhD, MBA – Global Head, Asia and Emerging Markets Partnering, Roche
  • Kumar Srinivasan, PhD, MBA – VP, Scientific Partnering and Alliances, AstraZeneca
  • Jimmy Zhang, PhD, MBA – VP Transaction, Johnson & Johnson Innovation
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–11:00
Grand Ballroom
Networking Break
Grand Ballroom
10:30–17:00
One-to-one Meetings ►
11:00–12:00
Plenary Panel
Innovation: The evolution of R&D in Chinese pharma

Wednesday, 11:00–12:00
K2 & K3

China's pharmaceutical industry is rapidly evolving from a focus on generics and "me better" drugs to one focused on innovation. This is being driven in part by market needs, as China seeks higher quality therapeutics for a wealthier population. Central, provincial and local governments have also created over 150 funding programs for new drug development that can provide up to USD 10 million per grant. Universities and institutes are playing a key role in the evolution to innovation, creating the majority of NME patents in China. Returnees are also seeding the industry with the expertise and experience necessary to create novel medicines in China. This panel will focus on the shift toward innovation across the industry from the universities and institutes, to the new generation of China's pharmaceutical companies.

Moderator:
Li Wang, PhD – Director, Scientific Partnering and Alliances, AstraZeneca

Panelists:
  • Jun Bao, PhD, MBA – Senior VP and Chief Business Officer, Shenogen Pharma Group
  • Shaojing Hu, PhD – Chief Scientist in Medicinal Chemistry, Zhejiang Beta Pharma Inc.
  • Yang Ye, PhD – Deputy Director General, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • Yizhun Zhu, MD, PhD – Dean, School of Pharmacy, Fudan University
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–13:30
Grand Ballroom, K7 & K8
Luncheon
K4
13:00–17:00
Company Presentations ►
13:30–14:30
Panel Discussion
Commercializing therapeutics in China's new era

Wednesday, 13:30–14:30
K2 & K3

Already the fastest growing pharmaceutical market in the world, China is on the verge of surpassing Japan to become the #2 market next year. This growth is creating tremendous opportunity for the commercialization of therapeutics and related products and services in China. But along with this opportunity come challenges. China is a complex and fragmented market that can be difficult to reach, requiring complicated distribution and sales structures. Compliance with domestic and foreign regulations can create additional complexities and potential for government scrutiny. This panel will explore the pros and cons of various commercialization approaches in China—partnerships, JVs, internal sales structures, etc.—as well as how best to deal with the rapidly evolving environment to optimize success while minimizing risk.

Moderator:
Yuwen Liu, MBA – Chairwoman and CEO, BioBay

Speakers:
  • Robert Braithwaite – CEO and Co-Founder, Luqa Pharmaceuticals
  • Søren Kjeld Kristensen – General Manager, Lundbeck China and Hong Kong
  • Victor Shi, PhD – President Asia Pacific, QIAGEN
  • Bo Tan, MBA – Executive VP and CFO, 3SBio Inc.
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:30–15:30
Workshop
Effective strategies for cross-border drug approval

Wednesday, 14:30–15:30
K2 & K3

There are many potential approaches to gaining drug approval from the China's CFDA in conjunction with US, EU and/or other market approvals. Cost, timing, and target markets are all factors that should be considered. Is it better to begin pre-clinical studies in China to save costs, or is the US faster IND approval an advantage? Should parallel studies be performed in each market, or is it better to wait until US/EU approval, then do a small Phase III in China for approval as an imported product? Or, perhaps perform a cohort of your Phase III in China to gain approval shortly after US/EU approval? Our panel of regulatory experts will examine the various strategies and discuss the pros and cons of each.

Moderator:
Ling Su, PhD – Strategic Advisor, Life Sciences, Sidley Austin LLP

Speakers:
  • Hua Mu, MD, PhD – Senior VP of Operations and Global Head of the Product Development Service and Partnership Business Unit, WuXi AppTec
  • Peng Wang, PhD – President of R&D, Yabao Pharmaceutical Group
  • Jimmy Wei, PhD, MBA – Venture Partner, KPCB China
  • Dajun Yang, MD, PhD – President and CEO, Ascentage Pharma Group, Co., Ltd.
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–16:00
Networking Break
16:00–17:00
Panel Discussion
VC funding in China: Who's got the money and how do you get it?

Wednesday, 16:00–17:00
K2 & K3

Venture investment activity continued its three-year upward trend in 2013, with nearly USD 1 billion being invested in life science companies in China. This funding came from a variety of sources including international VCs, domestic VCs, and government funds. RMB-based funds for life science are increasing in China, while many of the funds are still offshore and primarily USD-based. This panel of experienced venture capitalists, all active in the life science space, will discuss trends in VC investment in China, what are the best sources for investment, and what you, as an entrepreneur, need to do to convince the VCs that your company is the next Genentech.

Moderator:
Greg B. Scott – President and Founder, ChinaBio® LLC

Panelists:
  • Nisa Leung, MBA – Managing Partner, Qiming Venture Partners
  • Sofie Qiao, PhD – Managing Director, Venture Fund Department, WuXi AppTec
  • Jun Wu, PhD – Chairman and Managing Partner, Cenova Ventures
  • Rachel Zhao – Principal, BVCF
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:00–18:00
Exhibit Hall Champagne Reception
18:30–21:00
Gala Reception
The Noble Club

Crowne Plaza Suzhou
168 Xinggang Street
Suzhou Industrial Park
Suzhou, China

Sponsored by:

Roche Roche

18:00–18:30 Shuttle buses will transport guests from hotel to evening event
21:00–21:30 Shuttle buses will transport guests from evening event to hotel

Note: There will also be an optional tour of the BioBay life science park with buses leaving at 17:30, which will also take you to the Gala Reception after the tour.

Thursday, May 8, 2014
08:00
Hotel Lobby
Registration opens
08:00–09:00
Grand Ballroom
Continental Breakfast
09:30–11:45
K2 & K3
Pharma company presentations
Johnson & Johnson Innovation

Johnson & Johnson Innovation
Thursday, 09:30–09:45
K2 & K3

Speaker:
  • Mingde Xia, PhD – Senior Director, Johnson & Johnson Innovation
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:45–10:00
Lundbeck

Lundbeck
Thursday, 09:45–10:00
K2 & K3

Speaker:
  • Zheng Li, PhD – General Manager, Lundbeck
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:00–10:15
Novo Nordisk

Novo Nordisk
Thursday, 10:00–10:15
K2 & K3

Speaker:
  • Anand Gautam, PhD – Director, Biopharm Innovation Sourcing, Novo Nordisk
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bristol-Myers Squibb

Bristol-Myers Squibb
Thursday, 10:15–10:30
K2 & K3

Speaker:
  • Jie D'Elia, PhD, MBA – Executive Director, Business Development, Bristol-Myers Squibb
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30–10:45
Merck Serono

Merck Serono
Thursday, 10:30–10:45
K2 & K3

Speaker:
  • Will Liu, PhD – Head of External Innovation China, Merck Serono
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bayer HealthCare AG

Bayer HealthCare AG
Thursday, 10:45–11:00
K2 & K3

Speaker:
  • Nicolas Becker – Head, Business Development and Licensing, Bayer HealthCare China
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:00–11:15
Roche

Roche
Thursday, 11:00–11:15
K2 & K3

Speaker:
  • Darren Ji, MD, PhD, MBA – Global Head, Asia and Emerging Markets Partnering, Roche
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:15–11:30
AstraZeneca

AstraZeneca
Thursday, 11:15–11:30
K2 & K3

Speaker:
  • Ajay Gautam – Executive Director and Head of External Collaborations, Asia and Emerging Markets iMed, AstraZeneca
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:30–11:45
Eli Lilly

Eli Lilly
Thursday, 11:30–11:45
K2 & K3

Speaker:
  • Robert Narquizian, PhD, MBA – Director and Head of Global External R&D China, Asia Pacific – Emerging Markets, Eli Lilly
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Grand Ballroom
09:00–16:00
One-to-one Meetings ►
12:00–13:30
Grand Ballroom, K7 & K8
Luncheon
13:30–14:30
Panel Discussion
Top deals dissected: Where are they now?

Thursday, 13:30–14:30
K2 & K3

There have been over 400 partnering deals in China in the last five years, and 85% of the pharma deals were cross-border. But what has resulted from these deals? While it's impossible to look at all 400, our panel of BD and R&D executives will explore some of the partnerships they have helped put together in the last few deals, from early stage academia as well as development stage deals, to see where they are now.

Moderator:
Christina Zhang, JD – Partner, Cooley LLP, Shanghai

Panelists:
  • Yuan-hua Ding, PhD – Head, External R&D Innovation, Asia Pacific, Pfizer Inc.
  • Ajay Gautam – Executive Director and Head of External Collaborations, Asia and Emerging Markets iMed, AstraZeneca
  • May Wang, PhD – Senior VP, Head of BD and Strategic Alliance, Hutchison MediPharma
  • Jingsong Wang, MD – Head of China R&D, Head of Translational Medicine Asia Pacific, Sanofi
ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:30–15:30
Fireside Chat
Executive interview: A returnee's perspective

Thursday, 14:30–15:30
K2 & K3

Dr. Steve Yang is one of the most prominent and well respected "returnees" to China who has helped lead China's evolution toward true innovation. After returning to China eight years ago and leading Asia R&D at two of the big pharma in Shanghai, Dr. Yang has now joined one of the companies that has was responsible for that evolution, WuXi AppTec. Dr. Yang was also a co-founder of BayHelix, the first cross-border organization of Chinese pharma executives. Dr. Yang brings a unique perspective on the changes in the industry he and WuXi have brought about, especially from a cross-border perspective, which he will share in this one-on-one interview.

Interviewee:
Steve Yang, PhD – Executive VP and Chief Operating Officer, WuXi AppTec

Interviewed by:
Eric Pierce – Publisher - BioCentury

ChinaBio® Partnering Forum 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
K4
13:30–16:15
Company Presentations ►
15:30–16:30
Grand Ballroom
Closing Reception
Arrow Up


© 2009–2014 EBD Group, Inc.
ChinaBio Partnering Forum EBD GroupChinaBIO